Alzheimer’s Disease is projected to increase to 30 million people in the next 30 years and the rate of
diabetes mellitus is projected to rise also.
Hyperglycemia is commonly observed in patients with
diabetes mellitus, and hypoglycemia is a common consequence due to insulin therapy. Previous research has shown a potential link between Alzheimer’s disease and diabetes. This study sought to determine if Astaxanthin (ATX) could prevent mitochondrial dysfunction from the compounded effects of amyloid β (Aβ) plaque and hypoglycemia or hyperglycemia. Growth patterns, ATP production, and ROS generation were examined in 2 μM, 5 μM, 25 μM (hypoglycemic groups), 2 mM, 5 mM (normal groups), and 25 mM glucose (hyperglycemic group), and then treated with or without ATX or Aβ. When hypoglycemia groups and the
hyperglycemia group were treated with ATX, their growth patterns were either comparable to control or increased. ATX and Aβ treated
cells demonstrated increased growth patterns over
cells treated with Aβ alone. Aβ alone treated groups overall had significantly less growth than controls (p < 0.05). Hypoglycemic groups produced overall low levels of ATP, and the
hyperglycemia group produced high levels of ATP.
High Impact List of Articles
Relevant Topics in Neuroscience & Psychology
